Future directions in inflammatory bowel disease management

Journal of Crohn's and Colitis

Volumn 8, Issue 8, 2014, Pages 726-734

  D'Haens, Geert R ^a   Sartor, R Balfour ^b   Silverberg, Mark S ^c   Petersson, Joel ^d   Rutgeerts, Paul ^e  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d ABBVIE INC   (United States)

^e UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Algorithms; Biosimilars; Crohn's disease; Microbiome; Prognostics; Ulcerative colitis

Indexed keywords

BIOLOGICAL MARKER; BIOSIMILAR AGENT; ABRILUMAB; CHEMOKINE RECEPTOR CCR9 ANTAGONIST; INTERLEUKIN 13 ANTIBODY; INTERLEUKIN 6 ANTIBODY; PREBIOTIC AGENT; TOFACITINIB; TOLL LIKE RECEPTOR AGONIST; USTEKINUMAB; VEDOLIZUMAB; VERCIRNON;

ALGORITHM; BIOLOGICAL THERAPY; DISEASE COURSE; GENOMICS; HUMAN; INFLAMMATORY BOWEL DISEASE; MICROBIOME; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL (TOPIC); FECES MICROFLORA; PROGNOSIS; COLITIS, ULCERATIVE; CROHN DISEASE; FORECASTING; GENETICS; INFLAMMATORY BOWEL DISEASES; MEDICAL RESEARCH;

BIOMEDICAL RESEARCH; BIOSIMILAR PHARMACEUTICALS; COLITIS, ULCERATIVE; CROHN DISEASE; FORECASTING; HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 84904460389     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2014.02.025     Document Type: Review

References (84)

1. Dignass A., Lindsay J.O., Sturm A., Windsor A., Colombel J.F., Allez M., et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012, 6:991-1030.
2. Dignass A., Van Assche G., Lindsay J.O., Lemann M., Soderholm J., Colombel J.F., et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010, 4:28-62.
3. Rutgeerts P. How to guide therapeutic decisions in a patient-tailored approach to treatment of IBD?. Dig Dis 2012, 30:396-399.
4. Casellas F., Barreiro de Acosta M., Iglesias M., Robles V., Nos P., Aguas M., et al. Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2012, 24:762-769.
5. Lichtenstein G.R., Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis 2010, 16:338-346.
6. Froslie K.F., Jahnsen J., Moum B.A., Vatn M.H. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007, 133:412-422.
7. Schnitzler F., Fidder H., Ferrante M., Noman M., Arijs I., Van Assche G., et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009, 15:1295-1301.
8. De Cruz P., Kamm M.A., Prideaux L., Allen P.B., Moore G. Mucosal healing in Crohn's disease: a systematic review. Inflamm Bowel Dis 2013, 19:429-444.
9. Baert F., Moortgat L., Van Assche G., Caenepeel P., Vergauwe P., De Vos M., et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010, 138:463-468.
10. D'Haens G., Baert F., van Assche G., Caenepeel P., Vergauwe P., Tuynman H., et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008, 371:660-667.
11. Schreiber S., Reinisch W., Colombel J.F., Sandborn W.J., Hommes D.W., Robinson A.M., et al. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3years for adalimumab-treated patients with early Crohn's disease. J Crohns Colitis 2013, 7:213-221.
12. Schreiber S., Colombel J.F., Bloomfield R., Nikolaus S., Scholmerich J., Panes J., et al. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol 2010, 105:1574-1582.
13. Colombel J.F., Sandborn W.J., Reinisch W., Mantzaris G.J., Kornbluth A., Rachmilewitz D., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010, 362:1383-1395.
14. Devlin S.M., Cheifetz A.S., Siegel C.A., BRIDGe Group Patient-specific approach to combination versus monotherapy with the use of antitumor necrosis factor alpha agents for inflammatory bowel disease. Gastroenterol Clin North Am 2012, 41:411-428.
15. Lin M.V., Blonski W., Lichtenstein G.R. What is the optimal therapy for Crohn's disease: step-up or top-down?. Expert Rev Gastroenterol Hepatol 2010, 4:167-180.
16. Blonski W., Buchner A.M., Lichtenstein G.R. Inflammatory bowel disease therapy: current state-of-the-art. Curr Opin Gastroenterol 2011, 27:346-357.
17. Regueiro M., Schraut W., Baidoo L., Kip K.E., Sepulveda A.R., Pesci M., et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009, 136:441-450.
18. Sorrentino D., Paviotti A., Terrosu G., Avellini C., Geraci M., Zarifi D. Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease. Clin Gastroenterol Hepatol 2010, 8:591-599.
19. Colombel J.F., Feagan B.G., Sandborn W.J., Van Assche G., Robinson A.M. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis 2012, 18:349-358.
20. Afif W., Loftus E.V., Faubion W.A., Kane S.V., Bruining D.H., Hanson K.A., et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010, 105:1133-1139.
21. Bendtzen K., Ainsworth M., Steenholdt C., Thomsen O.O., Brynskov J. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol 2009, 44:774-781.
22. Rutgeerts P., Sandborn W.J., Feagan B.G., Reinisch W., Olson A., Johanns J., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476.
23. Hanauer S.B., Wagner C.L., Bala M., Mayer L., Travers S., Diamond R.H., et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004, 2:542-553.
24. Chaparro M., Panes J., Garcia V., Manosa M., Esteve M., Merino O., et al. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response. J Clin Gastroenterol 2011, 45:113-118.
25. Miheller P., Kiss L.S., Lorinczy K., Lakatos P.L. Anti-TNF trough levels and detection of antibodies to anti-TNF in inflammatory bowel disease: are they ready for everyday clinical use?. Expert Opin Biol Ther 2012, 12:179-192.
26. Vande Casteele N., Brecx S., Declerck P., Ferrante M., Rutgeerts P., Vermeire S., et al. Letter: dry blood spots for anti-TNF treatment monitoring in IBD. Aliment Pharmacol Ther 2013, 37:1024-1025.
27. Best W.R., Becktel J.M., Singleton J.W., Kern F. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976, 70:439-444.
28. Harvey R.F., Bradshaw J.M. A simple index of Crohn's-disease activity. Lancet 1980, 1:514.
29. Guyatt G., Mitchell A., Irvine E.J., Singer J., Williams N., Goodacre R., et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989, 96:804-810.
30. Irvine E.J. Development and subsequent refinement of the inflammatory bowel disease questionnaire: a quality-of-life instrument for adult patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1999, 28:S23-S27.
31. Louis E., Vermeire S., Rutgeerts P., De Vos M., Van Gossum A., Pescatore P., et al. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol 2002, 37:818-824.
32. Jurgens M., Mahachie John J.M., Cleynen I., Schnitzler F., Fidder H., van Moerkercke W., et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol 2011, 9:421-427.
33. Kiss L.S., Szamosi T., Molnar T., Miheller P., Lakatos L., Vincze A., et al. Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease. Aliment Pharmacol Ther 2011, 34:911-922.
34. Roseth A.G., Aadland E., Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 2004, 39:1017-1020.
35. Sipponen T., Bjorkesten C.G., Farkkila M., Nuutinen H., Savilahti E., Kolho K.L. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scand J Gastroenterol 2010, 45:325-331.
36. Rismo R., Olsen T., Cui G., Christiansen I., Florholmen J., Goll R. Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis. Scand J Gastroenterol 2012, 47:538-547.
37. Arijs I., Quintens R., Van Lommel L., Van Steen K., De Hertogh G., Lemaire K., et al. Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease. Inflamm Bowel Dis 2010, 16:2090-2098.
38. Jurgens M., Laubender R.P., Hartl F., Weidinger M., Seiderer J., Wagner J., et al. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am J Gastroenterol 2010, 105:1811-1819.
39. Arijs I., Li K., Toedter G., Quintens R., Van Lommel L., Van Steen K., et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut 2009, 58:1612-1619.
40. Kohane I.S., Drazen J.M., Campion E.W. A glimpse of the next 100years in medicine. N Engl J Med 2012, 367:2538-2539.
41. D'Haens G., Feagan B., Colombel J.F., Sandborn W.J., Reinisch W., Rutgeerts P., et al. Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease. Gastroenterology 2012, 143:1461-1469.
42. Travis S., Feagan B.G., Rutgeerts P., van Deventer S. The future of inflammatory bowel disease management: combining progress in trial design with advances in targeted therapy. J Crohns Colitis 2012, 6(Suppl. 2):S250-S259.
43. World Health Organization Expert Committee on Biological Standardization. Guidelines on Evaluation of Similar Biotherapeutic Products 2009, World Health Organization, Geneva, [Available at: http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf].
44. Declerck P.J. Biosimilar monoclonal antibodies: a science-based regulatory challenge. Expert Opin Biol Ther 2013, 13:153-156.
45. Mellstedt H., Niederwieser D., Ludwig H. The challenge of biosimilars. Ann Oncol 2008, 19:411-419.
46. Schiestl M., Stangler T., Torella C., Cepeljnik T., Toll H., Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 2011, 29:310-312.
47. Dorner T., Strand V., Castaneda-Hernandez G., Ferraccioli G., Isaacs J.D., Kvien T.K., et al. The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis 2013, 72:322-328.
48. Scheinberg M.A., Kay J. The advent of biosimilar therapies in rheumatology-"O brave new world". Nat Rev Rheumatol 2012, 8:430-436.
49. European Medicines Agency Committee for Medicinal Products for Human Use. Guideline on Similar Biological Medicinal Products Containing Monoclonal Antibodies - Non-clinical and Clinical Issues 2012, European Medicines Agency, London, [Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf].
50. US Food and Drug Administration Guidance for Industry. Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product. Draft Guidance 2012, US Food and Drug Administration, [Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.pdf].
51. Schneider C.K., Vleminckx C., Gravanis I., Ehmann F., Trouvin J.H., Weise M., et al. Setting the stage for biosimilar monoclonal antibodies. Nat Biotechnol 2012, 30:1179-1185.
52. Ebbers H.C., Crow S.A., Vulto A.G., Schellekens H. Interchangeability, immunogenicity and biosimilars. Nat Biotechnol 2012, 30:1186-1190.
53. Chamberlain P. Assessing immunogenicity of biosimilar therapeutic monoclonal antibodies: regulatory and bioanalytical considerations. Bioanalysis 2013, 5:561-574.
54. Yoo D.H., Hrycaj P., Miranda P., Ramiterre E., Piotrowski M., Shevchuk S., et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013, 72:1613-1620.
55. Blackstone E.A., Fuhr J.P. Innovation and competition: will biosimilars succeed?: the creation of an FDA approval pathway for biosimilars is complex and fraught with hazard. Yes, innovation and market competition are at stake. But so are efficacy and patient safety. Biotechnol Healthc 2012, 9:24-27.
56. Eckburg P.B., Relman D.A. The role of microbes in Crohn's disease. Clin Infect Dis 2007, 44:256-262.
57. Elson C.O., Cong Y., McCracken V.J., Dimmitt R.A., Lorenz R.G., Weaver C.T. Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. Immunol Rev 2005, 206:260-276.
58. Peterson D.A., Frank D.N., Pace N.R., Gordon J.I. Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases. Cell Host Microbe 2008, 3:417-427.
59. Sartor R.B. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008, 134:577-594.
60. Sokol H., Lay C., Seksik P., Tannock G.W. Analysis of bacterial bowel communities of IBD patients: what has it revealed?. Inflamm Bowel Dis 2008, 14:858-867.
61. Albenberg L.G., Lewis J.D., Wu G.D. Food and the gut microbiota in inflammatory bowel diseases: a critical connection. Curr Opin Gastroenterol 2012, 28:314-320.
62. Frank D.N., St Amand A.L., Feldman R.A., Boedeker E.C., Harpaz N., Pace N.R. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A 2007, 104:13780-13785.
63. Frank D.N., Robertson C.E., Hamm C.M., Kpadeh Z., Zhang T., Chen H., et al. Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. Inflamm Bowel Dis 2011, 17:179-184.
64. Prantera C., Lochs H., Grimaldi M., Danese S., Scribano M.L., Gionchetti P., et al. Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. Gastroenterology 2012, 142:473-481. [e4].
65. Gionchetti P., Rizzello F., Venturi A., Brigidi P., Matteuzzi D., Bazzocchi G., et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000, 119:305-309.
66. Venturi A., Gionchetti P., Rizzello F., Johansson R., Zucconi E., Brigidi P., et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999, 13:1103-1108.
67. Kuisma J., Mentula S., Jarvinen H., Kahri A., Saxelin M., Farkkila M. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther 2003, 17:509-515.
68. Sokol H., Pigneur B., Watterlot L., Lakhdari O., Bermudez-Humaran L.G., Gratadoux J.J., et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 2008, 105:16731-16736.
69. Atarashi K., Tanoue T., Shima T., Imaoka A., Kuwahara T., Momose Y., et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science 2011, 331:337-341.
70. Atarashi K., Tanoue T., Oshima K., Suda W., Nagano Y., Nishikawa H., et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 2013, 500:232-236.
71. Wu G.D., Chen J., Hoffmann C., Bittinger K., Chen Y.Y., Keilbaugh S.A., et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 2011, 334:105-108.
72. Devkota S., Wang Y., Musch M.W., Leone V., Fehlner-Peach H., Nadimpalli A., et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/- mice. Nature 2012, 487:104-108.
73. Borody T.J., Campbell J. Fecal microbiota transplantation: techniques, applications, and issues. Gastroenterol Clin North Am 2012, 41:781-803.
74. Borody T.J., Khoruts A. Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol 2012, 9:88-96.
75. Khoruts A., Dicksved J., Jansson J.K., Sadowsky M.J. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol 2010, 44:354-360.
76. van Nood E., Vrieze A., Nieuwdorp M., Fuentes S., Zoetendal E.G., de Vos W.M., et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013, 368:407-415.
77. Anderson J.L., Edney R.J., Whelan K. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther 2012, 36:503-516.
78. Jostins L., Ripke S., Weersma R.K., Duerr R.H., McGovern D.P., Hui K.Y., et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012, 491:119-124.
79. Plevy S., Silverberg M.S., Lockton S., Stockfisch T., Croner L., Stachelski J., et al. Combined serological, genetic, and inflammatory markers differentiate non-IBD, Crohn's disease, and ulcerative colitis patients. Inflamm Bowel Dis 2013, 19:1139-1148.
80. Haritunians T., Taylor K.D., Targan S.R., Dubinsky M., Ippoliti A., Kwon S., et al. Genetic predictors of medically refractory ulcerative colitis. Inflamm Bowel Dis 2010, 16:1830-1840.
81. Henckaerts L., Van Steen K., Verstreken I., Cleynen I., Franke A., Schreiber S., et al. Genetic risk profiling and prediction of disease course in Crohn's disease patients. Clin Gastroenterol Hepatol 2009, 7:972-980. [e2].
82. Lichtenstein G.R., Targan S.R., Dubinsky M.C., Rotter J.I., Barken D.M., Princen F., et al. Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behavior. Inflamm Bowel Dis 2011, 17:2488-2496.
83. Tyler A.D., Milgrom R., Stempak J.M., Xu W., Brumell J.H., Muise A.M., et al. The NOD2insC polymorphism is associated with worse outcome following ileal pouch-anal anastomosis for ulcerative colitis. Gut 2013, 62:1433-1439.
84. Kabakchiev B., Turner D., Hyams J., Mack D., Leleiko N., Crandall W., et al. Gene expression changes associated with resistance to intravenous corticosteroid therapy in children with severe ulcerative colitis. PLoS One 2010, 5:e13085.